Last reviewed 2026-04-20 · How we verify

Daybue (TROFINETIDE)

Daybue works by interacting with a specific target in the body to help manage symptoms of Rett syndrome.

At a glance

Mechanism of action

The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.

Approved indications

• Rett Syndrome Treatment

Common side effects

• Diarrhea
• Vomiting
• Fever
• Seizure
• Anxiety
• Decreased appetite
• Fatigue
• Nasopharyngitis

Drug interactions

• CYP3A and/or P-gp sensitive substrates

Key clinical trials

• Cognitive Function in Rett Syndrome During Trofinetide Treatment
• Open-Label Extension Study of Trofinetide for Rett Syndrome (PHASE3)
• An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome (PHASE2,PHASE3)
• Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (PHASE3)
• Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) (PHASE3)
• A Safety Study of NNZ-2566 in Pediatric Rett Syndrome (PHASE2)
• Study of NNZ-2566 in Patients With Traumatic Brain Injury (PHASE2)
• A Safety Study of NNZ-2566 in Patients With Rett Syndrome (PHASE2)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Daybue CI brief — competitive landscape report
• Daybue updates RSS · CI watch RSS
• Acadia Pharms Inc portfolio CI